Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.64 |
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525468 | 0.83 | CNR1 (0.64) | CNR1CNR2KDM4E | |
| SCHEMBL13225972 | 0.82 | CNR1 (0.81) | CNR1CNR2KDM4E | |
| SCHEMBL7329638 | 0.80 | KDM4E (0.57) | CNR1CNR2KDM4EALDH1A1GAA | |
| SCHEMBL13225969 | 0.79 | CNR1 (0.98) | CNR1CNR2 | |
| SCHEMBL13225970 | 0.79 | CNR1 (1.00) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3518579 | 0.78 | CNR1 (0.98) | CNR1CNR2 | |
| SCHEMBL3523176 | 0.77 | CNR1 (0.70) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3521099 | 0.76 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL3966675 | 0.72 | KDM4E (0.67) | CNR1CNR2KDM4EALDH1A1GAA | |
| SCHEMBL3965154 | 0.72 | KDM4E (0.67) | CNR1CNR2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772227-B2 | Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid CB1 receptor agonists | N.V. ORGANON (NL) | 2010-08-10 | — | — | US | disclosed |
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | AKZO NOBEL N.V. (NL) | 2007-04-19 | — | — | US | disclosed |
| EP-1696930-B1 | TRICYCLIC 1-((3-INDOL-3-YL)CARBONYL)PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS | ORGANON NV (NL) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088025-A1 | such as (R)-3-Cyclohexyl-2,3-dihydro-6-(4-ethylpiperazin-1-ylcarbonyl)pyrrolo[1,2,3-de]-1,4-benzoxazine hydrochloride salt, used as analgesics for the treatment of post-operative pain, chronic pain neuropathic pain, cancer pain and spasticity associated with multiple sclerosis | OPRD1, OPRK1, OPRM1 | CNR1 4/4885CNR2 6/4885KDM4E 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.